Candesartan-Based Treatment for Variability Lowering of Individual Blood Pressure and Heart Rate at Home Study
Not Applicable
- Conditions
- hypertension
- Registration Number
- JPRN-UMIN000005262
- Lead Sponsor
- Department of Internal Medicine Division of Cardio-vascular Medicine, Kurume University School of Medicine
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 928
Inclusion Criteria
Not provided
Exclusion Criteria
1. Poorly controlled hypertension (DBP greater than 120mmHg) 2. Poorly controlled diabetic patients (HbA1c greater than 9.0%) 3. Gout or serum uric acid greater than 8.0mg/dL 4. Renal insufficiency (serum creatinine greater than 2.0mg/dl) 5. Hyperkalimia (K greater than 5.5 mmol/L) 6. Liver damage (gamma-GTP or ALT greater than 3 x normal upper limit) 7. Endocrine secondary hypertension 8. Malignant hypertension 9. Contraindication for candesartan, amlodipine, orHCTZ 10. Prescribed ARB/CCB tablet or ARB/HCTZ tablet before registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Day-to-day variability (standard deviation and coefficiency of variance) of self-measured home systolic BP and heart rate after 6-month treatment
- Secondary Outcome Measures
Name Time Method 1. Visit-to-visit variability of casual BP and heart rate at every clinic visit 2. [morning BP]-[evening BP] 3. Achievement ratios of BP targets (casual BP, morning BP, and evening BP) 4. Changes in circulating levels of hsCRP, hsTnT, NT-proBNP, and collage III N-terminal peptide after 6-month treatment 5. Change in urine microalbumin after 6-month treatment 6. Tolerability and adverse effects